# US 2004/0019916 A1 · In vivo homologous sequence targeting in eukaryotic cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0019916 A1
- Document ID: US20040019916A1
- Status: Published application
- Kind: A1
- Application number: 10/379,182
- Filed: 2003-03-03
- Published: 2004-01-29
- Earliest claimed: 1992-04-24
- Inventors: David A. Zarling; Elissa P. Sena
- Web page: https://patentgrep.com/patent/US20040019916A1

## CPC

- C12N 15/907: {in mammalian cells}
- C07K 14/4712: {Cystic fibrosis}
- C07K 14/82: Translation products from oncogenes
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The invention relates to methods for targeting an exogenous polynucleotide or exogenous complementary polynucleotide pair to a predetermined endogenous DNA target sequence in a eukaryotic cell by homologous pairing, particularly for altering an endogenous DNA sequence, such as a chromosomal DNA sequence, typically by targeted homologous recombination. In certain embodiments, the invention relates to methods for targeting an exogenous polynucleotide having a linked chemical substituent to a predetermined endogenous DNA sequence in a metabolically active eukaryotic cell, generating a DNA sequence-specific targeting of one or more chemical substituents in an intact nucleus of a metabolically active eukaryotic cell, generally for purposes of altering a predetermined endogenous DNA sequence in the cell. The invention also relates to compositions that contain exogenous targeting polynucleotides, complementary pairs of exogenous targeting polynucleotides, chemical substituents of such polynucleotides, and recombinase proteins used in the methods of the invention.

## Claims

### Claim 1

A method for targeting and altering, by homologous recombination, a pre-selected target DNA sequence in a eukaryotic cell to make a targeted sequence modification, said method comprising the steps of:
introducing into at least one eukaryotic cell at least one recombinase and at least one targeting polynucleotide having a homology clamp that substantially corresponds to or is substantially complementary to a preselected target DNA sequence; and
identifying a eukaryotic cell having a targeted DNA sequence modification at a preselected target DNA sequence.

### Claim 2 (depends on 1)

A method according to claim 1, wherein at least two targeting polynucleotides which are substantially complementary to each other are used.

### Claim 3 (depends on 1)

A method according to claim 1, wherein said recombinase is a species of prokaryotic recombinase.

### Claim 4 (depends on 3)

A method according to claim 3, wherein said prokaryotic recombinase is a species of prokaryotic recA protein.

### Claim 5 (depends on 4)

A method according to claim 4, wherein said recA protein species is E. coli recA.

### Claim 6 (depends on 1)

A method according to claim 1, wherein said targeting polynucleotide is conjugated to a cell-uptake component.

### Claim 7 (depends on 6)

A method according to claim 6, wherein said cell-uptake component is conjugated to said targeting polynucleotide by noncovalent binding.

### Claim 8 (depends on 6)

A method according to claim 6, wherein the cell-uptake component comprises an asialoglycoprotein.

### Claim 9 (depends on 6)

A method according to claim 6, wherein the cell-uptake component comprises a protein-lipid complex.

### Claim 10 (depends on 6)

A method according to claim 6, wherein said targeting polynucleotide is conjugated to a cell-uptake component and to a recombinase, forming a cell targeting complex.

### Claim 11 (depends on 1)

A method according to claim 1, wherein said targeting polynucleotide comprises a homology clamp that is complementary to said preselected target DNA sequence.

### Claim 12 (depends on 11)

A method according to claim 11, wherein the targeting polynucleotide consists of a homology clamp.

### Claim 13 (depends on 2)

A method according to claim 2, wherein a first said targeting polynucleotide comprises a homology clamp that is complementary to said preselected target DNA sequence and a second said targeting polynucleotide comprises a homology clamp that corresponds to said preselected target DNA sequence.

### Claim 14 (depends on 13)

A method according to claim 13, wherein said first targeting polynucleotide consists of a homology clamp.

### Claim 15 (depends on 13)

A method according to claim 13, wherein the homology clamp of said first targeting polynucleotide and the homology clamp of said second targeting polynucleotide are complementary.

### Claim 16 (depends on 2)

A method according to claim 2, wherein a first said targeting polynucleotide comprises a homology clamp that is complementary to a preselected target DNA sequence.

### Claim 17 (depends on 16)

A method according to claim 16, wherein a second targeting polynucleotide comprises a homology clamp that is complementary to a sequence of said first targeting polynucleotide.

### Claim 18 (depends on 17)

A method according to claim 17, wherein said second targeting polynucleotide consists of a sequence that is complementary to the complete sequence of said first polynucleotide.

### Claim 20 (depends on 1)

A method according to claim 1, wherein the preselected target DNA sequence is unique in a haploid genome of said eukaryotic cell.

### Claim 21 (depends on 20)

A method according to claim 20, wherein the preselected target DNA sequence is unique in a diploid genome of said eukaryotic cell.

### Claim 22 (depends on 1)

A method according to claim 1, wherein the targeted sequence modification comprises a deletion of at least one additional nucleotide.

### Claim 23 (depends on 1)

A method according to claim 1, wherein the targeted sequence modification comprises the addition of at least one additional nucleotide.

### Claim 24 (depends on 23)

A method according to claim 23, wherein the targeted sequence modification corrects a human disease allele in a human cell.

### Claim 25 (depends on 24)

A method according to claim 24, wherein the human disease allele is a CFTR allele associated with cystic fibrosis.

### Claim 26 (depends on 1, 6)

A method according to claim 1 or claim 6, wherein the recombinase and the targeting polynucleotide are introduced into the eukaryotic cell simultaneously.

### Claim 27 (depends on 26)

A method according to claim 26, wherein the recombinase and the targeting polynucleotide are introduced into the eukaryotic cell by a method selected from the group consisting of: microinjection, electroporation, or contacting of the cell with a lipid-protein-targeting polynucleotide complex.

### Claim 28 (depends on 1)

A method according to claim 1, wherein the targeted sequence modification creates a sequence that encodes a polypeptide having a biological activity.

### Claim 29 (depends on 28)

A method according to claim 28, wherein the biological activity is an enzymatic activity.

### Claim 30 (depends on 28, 29)

A method according to claim 28 or claim 29, wherein the targeted sequence modification is in a human cell and encodes a human polypeptide.

### Claim 31 (depends on 30)

A method according to claim 30, wherein the targeted sequence modification is in a human oncogene or tumor suppressor gene sequence.

### Claim 32 (depends on 31)

A method according to claim 31, wherein the targeted sequence modification is in a human p53 sequence.

### Claim 33 (depends on 30)

A method according to claim 30, wherein the targeted sequence modification is in a human CFTR allele.

### Claim 34 (depends on 33)

A method according to claim 33, wherein the targeted sequence modification occurs in a human cell.

### Claim 35 (depends on 1)

A method according to claim 1, wherein the targeting polynucleotide comprises a homology clamp that is less than 500 nucleotides long.

### Claim 36 (depends on 35)

A method according to claim 35, wherein the targeting polynucleotide is less than 500 nucleotides long.

### Claim 37

A composition for producing a targeted modification of an endogenous DNA sequence, comprising a targeting polynucleotide and a recombinase.

### Claim 38 (depends on 37)

A composition according to claim 37, wherein the targeting polynucleotide is noncovalently bound to said recombinase.

### Claim 39 (depends on 37)

A composition according to claim 37, further comprising a cell-uptake component.

### Claim 40

A composition for producing a targeted sequence modification of a human disease allele, comprising a targeting polynucleotide containing a corrected sequence and a recombinase.

### Claim 41 (depends on 40)

A composition according to claim 40, further comprising a cell-uptake component.

### Claim 42 (depends on 40, 41)

A composition according to claim 40 or claim 41, wherein the human disease allele is a CFTR allele.

### Claim 43

A kit for therapy, monitoring, or prophylaxis of a genetic disease comprising a recombinase and a targeting polynucleotide.

### Claim 44 (depends on 43)

A kit for therapy, monitoring, or prophylaxis of a genetic disease according to claim 43, further comprising a cell-uptake component.

### Claim 45

A method for treating a disease of a animal harboring a disease allele, comprising administering to the animal a composition consisting essentially of a targeting polynucleotide for correcting the disease allele and a recombinase.

### Claim 46 (depends on 45)

A method according to claim 45, wherein the composition further comprises a cell-uptake component.

### Claim 47 (depends on 45)

An animal comprising an allele that has been corrected according to the method of claim 45.
